key: cord-0767964-tu5yky7m
authors: Fuglebjerg, Natascha Josephine Ulstrand; Jensen, Tomas Oestergaard; Hoyer, Nils; Ryrsø, Camilla Koch; Lindegaard, Birgitte; Harboe, Zitta Barrella
title: Silent hypoxia in patients with SARS CoV-2 infection before hospital discharge
date: 2020-07-11
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.07.014
sha: 7dcfe02307e7f08f54dac6ff4c7e241341ac8e53
doc_id: 767964
cord_uid: tu5yky7m

OBJECTIVE: To assess the degree of hypoxia and subjective dyspnea elicited by a 6-minute walking test (6MWT) in COVID-19 patients prior to discharge. METHODS: A 6MWT was performed in 26 discharge-ready COVID-19 patients without chronic pulmonary disease or cardiac failure. Heart rate, oxyhemoglobin saturation (SpO(2)), respiratory rate, and subjective dyspnea measured on the Borg CR-10 scale were measured before and immediately after the 6MWT, with continuous monitoring of SpO(2) and heart rate during the 6MWT. The 6MWT was terminated if SpO(2) dropped below 90%. A historical cohort of 204 patients with idiopathic pulmonary fibrosis (IPF) was used for comparison. RESULTS: 13 (50%) of the COVID-19 patients developed exercise-induced hypoxia (SpO(2) < 90%) during the 6MWT, of which one third had pulmonary embolism. COVID-19 patients experienced less hypoxia-related dyspnea during the 6MWT compared with patients with IPF. CONCLUSION: The 6MWT is a potential tool in the diagnosis of asymptomatic exercise-induced hypoxia in hospitalized COVID-19 patients prior to discharge. Due to important methodological limitations, further studies are needed to confirm our findings and to investigate their clinical consequences.

Anecdotal evidence is emerging that patients with COVID-19 may present with 'silent hypoxia', which refers to a discrepancy between the level of hypoxia and subjective dyspnea experienced by the patient (Couzin-Frankel, 2020) . This phenomenon is of potential concern among patients with chronically compromised end-organ perfusion, for example in ischemic heart disease, where the absence of dyspnea may permit an acute ischemic event to progress to a critical level without the usual early warning symptoms. We aimed to investigate whether silent hypoxia in adult COVID-19 patients ready for discharge can be elicited by a 6-minute walking test (6MWT).

Patients hospitalized with COVID-19 confirmed by polymerase chain reaction (PCR) testing at the University Hospital of Copenhagen, North Zealand, Denmark were eligible for inclusion at the time of planned discharge, which required resolution of fever and an oxyhemoglobin saturation (SpO 2 ) of 94% or above at rest, without supplementary oxygen. Patients with chronic lung diseases and New York Heart Association (NYHA) class II and above were excluded. The 6MWT was carried out according to the American Thoracic Society (ATS) statement from 2002 by trained pulmonary physiotherapists (ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories, 2002). Patients were instructed to walk the greatest distance possible in 6 min, at a self-determined pace, pausing to rest if needed. Heart rate (HR), SpO 2 , respiratory rate (RR), and dyspnoea rated between 1 and 10 on the Borg CR-10 dyspnea scale (Borg and Kaijser, 2006; Borg, 1982) were recorded before and immediately after the 6MWT. A PaO 2 below 80 mmHg (10.6 kPa) is generally considered pathological, while a PaO 2 of at least 60 mmHg (8 kPa), which correlates to an SpO 2 of 90%, is required to maintain sufficient tissue oxygenation (Hansen et al., 1984) . SpO 2 and HR were continuously monitored during the 6MWT. We assumed that patients with no history of chronic lung disease should be able to maintain an SpO 2 of 96% or above, even during physical activity (Casanova et al., 2011) . A previous prospective cohort of 204 patients with idiopathic pulmonary fibrosis (IPF), who also underwent the 6MWT according to the ATS guidelines, was used for comparison (Hoyer et al., 2019) .

Forty-seven consecutive patients were screened between April 16 and April 28, 2020, and all 26 eligible patients without exclusion criteria were included. The 6MWT was terminated early in 13 patients (50%) due to an SpO 2 below 90%. Baseline characteristics in patients who terminated the 6MWT early compared with those who completed the 6MWT, as well as baseline characteristics for the comparison group, are presented in Table 1 . COVID-19 patients with an SpO 2 below 90% during the 6MWT had only discrete increase in perceived dyspnea (Figure 1 ). Six patients who terminated the 6MWT early due to hypoxia were investigated with CT angiography and/or ventilation-perfusion scintigraphy in order to exclude pulmonary embolism (PE), which was confirmed in four patients. As a comparison group, IPF patients had a similar decline in SpO 2 , but they developed more pronounced concomitant worsening in the level of subjective dyspnea measured by the Borg scale (Figure 1) . COVID-19 patients had a mean peak score of 2.5 on Borg CR-10 (range 0-5) during the 6MWT, compared with 4.1 (range 0-10) in IPF patients.

In summary, nearly half of hospitalized COVID-19 patients without chronic pulmonary disease developed marked exerciseinduced hypoxia without accompanying subjective dyspnea at the time of discharge, and one third of patients who terminated the 6MWT early had PE. We interpret this as evidence of silent hypoxia.

Our study had several limitations. No previous studies have examined the role of the 6MWT in otherwise healthy adults with COVID-19 or other acute respiratory tract infections, although exercise-induced hypoxia has been used in the diagnosis and severity assessment of Pneumocystis jirovecii pneumonia in HIV-positive adults (Sauleda et al., 1994) . Clinical implications of this hypoxia are thus not well described, and we therefore decided to routinely terminate the 6MWT early if SpO 2 dropped below 90% for safety reasons. This could have led to underestimation of the relative degree of dyspnea in COVID-19 patients, since they were compared with a control group of IPF patients, who were all allowed to complete the 6MWT unless they developed chest pain, intolerable dyspnea, leg cramps, staggering, diaphoresis, or pale or ashen appearance, in accordance with the ATS guidelines. Furthermore, patients in our control group all had IPF, a condition resulting in hypoxic respiratory failure, and therefore increased tolerance to lower SpO 2 without subjective dyspnea was a possibility in this group.

We propose further, larger studies to confirm our findings using a more accurately matched prospective group of controls, and to investigate the clinical consequences of silent hypoxia in particular among patients at elevated risk of serious end-organ ischemic events after discharge to the community.

ATS statement: Guidelines for the six-minute walk test

A comparison between three rating scales for perceived exertion and two different work tests

Psychophysical bases of perceived exertion

Six Minute Walk Distance Project (ALAT). The 6-min walk distance in healthy subjects: Reference standards from seven countries

The mystery of the pandemic's 'happy hypoxia

Predicted Values for Clinical Exercise Testing 1-3

Risk factors for diagnostic delay in idiopathic pulmonary fibrosis

Simplified exercise test for the initial differential diagnosis of Pneumocystis carinii pneumonia in HIV antibody positive patients

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

The study was approved by the Danish Health and Medicines Authority (ID: 31À1521-264) and by the Danish Data Protection Agency (P-2020-375).

 Table 1 Baseline characteristics of 26 patients with COVID-19 undergoing the 6-minute walking test (6MWT) at hospital discharge and a historical cohort of 204 patients with idiopathic pulmonary fibrosis who underwent the same test.